BCDA vs. ONVO, GENE, COEP, CHRO, EVAX, EIGR, IKT, CELZ, ACOR, and TTNP
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Organovo (ONVO), Genetic Technologies (GENE), Coeptis Therapeutics (COEP), Chromocell Therapeutics (CHRO), Evaxion Biotech A/S (EVAX), Eiger BioPharmaceuticals (EIGR), Inhibikase Therapeutics (IKT), Creative Medical Technology (CELZ), Acorda Therapeutics (ACOR), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.
Organovo (NASDAQ:ONVO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
In the previous week, BioCardia had 7 more articles in the media than Organovo. MarketBeat recorded 10 mentions for BioCardia and 3 mentions for Organovo. BioCardia's average media sentiment score of 0.47 beat Organovo's score of 0.23 indicating that Organovo is being referred to more favorably in the media.
BioCardia has a net margin of -2,197.72% compared to BioCardia's net margin of -4,061.12%. BioCardia's return on equity of -182.88% beat Organovo's return on equity.
Organovo received 186 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 51.17% of users gave Organovo an outperform vote while only 47.62% of users gave BioCardia an outperform vote.
Organovo has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
BioCardia has a consensus target price of $4.00, suggesting a potential upside of 882.80%. Given Organovo's higher probable upside, analysts clearly believe BioCardia is more favorable than Organovo.
8.2% of Organovo shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 4.0% of Organovo shares are held by company insiders. Comparatively, 23.9% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioCardia has higher revenue and earnings than Organovo. BioCardia is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Summary
BioCardia beats Organovo on 10 of the 17 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BioCardia Competitors List
Related Companies and Tools